This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Other				
Poisoning	Solute carrier family 22 organic cation transporter member 2 (SLC22A2; OCT2)	<p>Mouse and cell culture studies suggest inhibiting OCT2 could help decrease oxaliplatin-induced neurotoxicity. In a human cell line, a small molecule OCT2 inhibitor decreased oxaliplatin uptake compared with no treatment. In mice receiving oxaliplatin, <i>Oct2</i> knockout lowered marker expression for oxaliplatin-induced neuropathy compared with no knockout. Next steps include evaluating the ability of OCT2-specific inhibitors in modulating oxaliplatin-induced neuropathy in patients with neurotoxicity.</p> <p>Oxaliplatin is a generic chemotherapeutic.</p> <p><i>SciBX</i> 6(28); doi:10.1038/scibx.2013.735 Published online July 25, 2013</p>	Unpatented; licensing status not applicable	<p>Sprowl, J.A. <i>et al. Proc. Natl. Acad. Sci. USA</i>; published online June 17, 2013; doi:10.1073/pnas.1305321110</p> <p>Contact: Alex Sparreboom, St. Jude Children's Research Hospital, Memphis, Tenn. e-mail: alex.sparreboom@stjude.org</p>